Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00704912
Other study ID # 27184
Secondary ID
Status Completed
Phase Phase 2
First received June 23, 2008
Last updated November 3, 2016
Start date September 2008
Est. completion date March 2014

Study information

Verified date November 2016
Source Milton S. Hershey Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The goal of this three-armed randomized controlled trial is to establish the relative roles of treatment of hyperandrogenism versus obesity (as the largest modifiable factor contributing to insulin resistance) in treating infertility and improving pregnancy outcomes among obese PCOS women. The investigators hypothesize that the key to restoring ovulation leading to live birth is to correct hyperandrogenism with oral contraceptive pills, but the key to avoiding later pregnancy complications is to improve insulin sensitivity with weight loss.


Description:

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility among women, and women with PCOS are at increased risk for pregnancy complications such as gestational diabetes and pre-eclampsia. Both hyperandrogenism (HA) and obesity exacerbated insulin resistance (IR) are characteristics of the syndrome, and are targets for treatment, but which should be the predominant focus is still unknown. Phase 1 of this study will be a randomized trial of three preconception interventions in infertile women with PCOS. The first arm will be a combined intervention of medication, meal replacements, and lifestyle modification to improve IR. Orlistat is a gastric lipase inhibitor that reduces the absorption of fat contained in a meal by about 30%. The second arm will be the use of a continuous OCP for 4 months to improve HA. Lo-Estrin 1/20 will be used in a continuous method for 4 months to suppress the ovary. The third arm is the combination of both to improve HA an IR. Phase II of this study will involve ovulation induction with clomiphene citrate with hopeful outcome of pregnancy. Finally, Phase III involve following the pregnancies for outcomes and complications.


Recruitment information / eligibility

Status Completed
Enrollment 217
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Couples Inclusion Criteria:

- Partner with sperm concentration of >=14 million/mL in at least one ejaculate with motile sperm.

- Ability to have regular intercourse 2-3 times per week during the ovulation induction phase of study.

- At least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years, or confirmation of a intrauterine pregnancy within the past 2 years.

- No previous sterilization procedures(vasectomy, tubal ligation) that have been reversed.

- Wanting to seek pregnancy.

Inclusion Criteria:

- Chronic anovulation or oligomenorrhea defined as intermenstrual periods of >= 45 days or a total of <=8 periods per year.

- Hyperandrogenism will be an elevated total testosterone >=50 ng/dL.

- Hirsutism determined by a modified Ferriman-Gallwey Score >8.

- PCO on ultrasound (12 or more follicles measuring 2-9 mm in diameter).

- BMI >=27 to <=42.

- Normal EKG to rule out any abnormalities with the heart.

Exclusion Criteria:

- Current pregnancy.

- Patients on oral contraceptives, depo progestins, or hormonal implants.

- Patients with hyperprolactinemia defined as two prolactin levels at least one week apart >30 ng/mL.

- Patients with known 21-hydroxylase deficiency by a fasting 17-hydroxyprogesterone (17-OHP) level <2 ng/mL and ACTH stimulation test as needed, or other enzyme deficiency.

- Patients with menopausal FSH levels >20 mIU/mL.

- Patients with uncorrected thyroid disease (TSH <0.45 mIU/ML or >4.5 mIU/ML).

- Patients diagnosed with Type1 or Type II diabetes.

- Patients with liver disease defined as AST or ALT >2 times normal or total bilirubin >2.5 mg/dL.

- Patients with renal disease defined as BUN >30 mg/dL or serum creatinine >1.4 mg/dL.

- Patients with significant anemia (Hemoglobin <10 mg/dL).

- Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.

- Patients with known heart disease that is likely to be exacerbated by pregnancy.

- Patients with a history of , or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal PAP smear or reassuring colposcopy based on current ACOG guidelines will be required.

- Patient with current history of alcohol abuse.

- Patients enrolled simultaneously into other investigative studies.

- Patients taking other medications know to affect reproductive function or metabolism.

- Patients with a suspected adrenal or ovarian tumor secreting androgens.

- Patients with suspected Cushing's syndrome.

- Patients who have undergone a bariatric surgery procedure in the recent past (<12 months).

- Patients with untreated poorly controlled hypertension defined as systolic blood pressure >=150 mm Hg or average diastolic >=100 mm Hg on three measurements obtained 5 minutes apart. If treated, average systolic blood pressure >= 140 mm Hg or average diastolic >= 90 mm Hg.

- Patients with medical conditions that represent contraindications to orlistat, OCP, clomiphene, and/or pregnancy.

- Patients currently participating in lifestyle intervention program (Weight Watchers, Atkins Diet, Curves) or lost more than 5% body weight within the last 6 months.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Orlistat/Meal Replacement/Lifestyle Modification
Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
Loestrin 1/20
Patients will be started on a low dose containing OCP for a continuous 4 month period.
Combination of treatments
Medications will be administered as described for the other 2 arms.

Locations

Country Name City State
United States Penn State College of Medicine, Penn State Milton S. Hershey Medical Center Hershey Pennsylvania
United States University of Pennsylvania, Department of Obstetrics and Gynecology Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Milton S. Hershey Medical Center University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Live Birth Rate Participants were followed for 4 months of attempted conception and those who conceived were then followed for the duration of their pregnancy, approximately 9 months. No
Secondary Ovulation Rate Up to 4 months No
Secondary Change in Weight Change from baseline to end of the 4-month intervention. Baseline, 4 months No
Secondary Prevalence of Metabolic Syndrome Baseline, 4 months No
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Completed NCT06158932 - A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04932070 - Berberine and Polycystic Ovary Syndrome N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT03043924 - Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT05246306 - Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
Completed NCT05981742 - Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Phase 2
Completed NCT05702957 - Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome Phase 2/Phase 3
Completed NCT05029492 - Effect of Visceral Manipulation on PCOS N/A
Not yet recruiting NCT02255578 - Endobarrier Treatment in Women With PCOS Phase 3
Completed NCT02924025 - Motivational Interviewing as an Intervention for PCOS N/A
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Withdrawn NCT01638988 - Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin Phase 3
Completed NCT01462864 - Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01431352 - Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT00989781 - Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome N/A